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Abstract: Since the original data from the Department of Vet-
erans Affairs Laryngeal Cancer Study Group demonstrated that
nonsurgical therapy could achieve survival rates comparable to
total laryngectomy in selected cases, there has been a progres-
sive increase in employment of nonsurgical therapy for the
management of advanced laryngeal cancer. Both neoadjuvant
chemotherapy followed by conventionally fractionated or hy-
perfractioned radiotherapy for chemotherapy responders, or
simultaneously administered chemoradiation has resulted in a
significant number of patients who achieved cure while preserv-
ing their larynges. Nevertheless, combined chemotherapy and
external beam radiation is associated with a variety of acute and
chronic sequelae that can have a debilitating impact on function
and quality of life. Although no therapeutic option is without risk,
the decision regarding the modality of therapy for a patient with
advanced laryngeal cancer should prompt a careful review ofVC 2007 Wiley Periodicals, Inc.
Correspondence to: A. Ferlito
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the current surgical techniques available for treatment. Data on
quality of life and aging, as well as advances in minimally inva-
sive surgical techniques, are available today that were not avail-
able at the time of the Veterans study. Selection of optimal ther-
apy is often complex and raises the question whether the pendu-
lum may have swung too far in the direction of nonsurgical
therapy for advanced laryngeal cancer. This article reviews the
current options available for a patient with advanced laryngeal
cancer and discusses the impact of therapy. VC 2007 Wiley
Periodicals, Inc. Head Neck 30: 103–110, 2008
Keywords: advanced laryngeal cancer; chemoradiotherapy;
chemotherapy; molecular therapy; quality of life
Cancer of the larynx is among the most common
cancers of the upper aerodigestive tract and is
diagnosed in nearly 10,000 men and women in the
United States annually.1 In the Developed World,
50% to 60% of patients present with early laryn-
geal cancer, defined by the American Joint Com-
mittee on Cancer as a T1 or T2 tumor without
nodal involvement or distant metastases.2 Ad-
vanced laryngeal cancer has been classified as
locally advanced laryngeal cancer, locoregionally
advanced laryngeal cancer, and disseminated la-
ryngeal cancer.3 It is generally accepted that the
term ‘‘advanced’’ corresponds to stages III and IV
of the TNM classification.
The current recommendations for the manage-
ment of advanced laryngeal cancer have been pub-
lished by the National Comprehensive Cancer
Network (NCCN).4 These recommendations re-
flect the results of several phase II and phase III
studies as well as the opinions of the members of
the committee assigned to the NCCN on head and
neck cancer. Although the guidelines are revised
every 2 years to reflect changing therapeutic
trends, new data on the management of advanced
laryngeal cancer and the impact of therapy are
constantly being published in an effort to improve
survival outcomes and quality of life (QOL). This
review is an update of current data and thinking




The Department of Veterans Affairs Laryngeal
Cancer Study Group (VALCSG)5 was the first to
demonstrate that nonsurgical therapy could
achieve survival rates comparable to the ‘‘gold
standard’’ of total laryngectomy, when neoadju-
vant (or ‘‘induction’’) chemotherapy was employed
to select those cases most likely to respond to radi-
ation therapy (RT). The study demonstrated little
difference in survival between total laryngectomy
with postoperative RT, and induction chemother-
apy followed by RT with surgery reserved for
chemotherapy nonresponders. This landmark
work demonstrated the potential value of nonsur-
gical therapy in achieving laryngeal preservation
(64%) with survival rates comparable to surgery
as primary treatment. Since this pioneering publi-
cation, the percentage of advanced-stage patients
treated with combined-modality chemotherapy
and RT, either sequentially or as chemoradiation,
increased from 8.3% to 20.8%, whereas the pro-
portion treated with RT alone decreased from
38.9% to 23.0%.2 The Radiation Therapy Oncol-
ogy Group (RTOG) (Head and Neck Intergroup)
(RTOG 91-11)6 subsequently demonstrated that
concomitant chemoradiation achieved higher
laryngeal preservation rates when compared with
induction chemotherapy followed by RT, or RT
alone. However, 5-year overall survival rates did
not differ by treatment.
Although these randomized trials have
changed the standard of care for advanced laryn-
geal cancer, there have been several criticisms of
these trials. These include the fact that many of
the tumors were considered ‘‘advanced’’ because
of nodal status, not because of primary stage.
Therefore patients with mobile cords might have
been candidates for conservation laryngeal sur-
gery, rather than total laryngectomy. It has also
been suggested that many of the patients in the
RTOG 91-11 trial had earlier stage disease than
those in the original VALCSG study, again sug-
gesting that these patients might have been can-
didates for conservation laryngectomy, not total
laryngectomy. Given the documented excellent
results with transoral laser microsurgery and
supracricoid partial laryngectomy,7–9 many argue
that these confounding factors may have favor-
ably influenced the overall survival rates and the
rate of laryngeal preservation. In 2006, Foote
et al10 addressed these concerns and found that it
is unlikely that the inclusion of patients with a
mobile vocal cord would have significantly
affected overall survival or laryngeal preservation
rate for either the VALCSG or RTOG 91-11 stud-
ies. Despite this report, and several others exam-
ining the results of these studies,8,11 many head
and neck oncologists have conflicting views about
optimal candidatures for nonsurgical therapy.
Although the VALCSG data5 suggested that
neoadjuvant chemotherapy failed to exert a signif-
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icant impact on overall survival, it and several
other studies have demonstrated that induction
chemotherapy may have an important role in the
contemporarymanagement of advanced laryngeal
cancer. It has become clear that while some
patients benefit from chemoradiation, there is
another subgroup that will not respond to chemo-
radiation and would benefit from initial total lar-
yngectomy and postoperative RT. This would sug-
gest that appropriate patient selection might be
the key to optimizing treatment outcome. The
VALCSG study employed 3 cycles of chemother-
apy to make this selection, thus delaying the insti-
tution of definitive treatment by several months.
In 2006, Urba et al12 conducted a phase II organ
preservation trial in 97 patients to determine if
late salvage surgery rates could be decreased and
survival improved by selecting patients for organ
preservation predicated on the response to a sin-
gle cycle of induction chemotherapy. One third of
the patients had T4 (cartilage invasion) primary
cancers. Of the 97 eligible patients, 73 (75%)
achieved more than 50% response and conse-
quently were treated with chemoradiation.
Twenty-nine (30%) of the total group underwent
salvage surgery. Twenty percent had early sal-
vage surgery after the single cycle of induction
chemotherapy produced less than a 50%
response. Three percent of patients had late sal-
vage surgery after failure of chemoradiation, and
6% of patients had salvage surgery for recur-
rence. Larynx preservation was achieved in 70%
of patients, and the 3-year cause-specific survival
rate was 87%, significantly better than an imme-
diately previous historical control cohort of com-
parable patients. This study confirmed the benefit
of single cycle induction chemotherapy in predict-
ing response to chemoradiation and suggested
that overall survival rates could be improved with
such an induction regimen.
In 2006,Majem et al13 studied 71 patients with
advanced laryngeal cancer who received induc-
tion chemotherapy with 3 cycles of cisplatin plus
fluorouracil. Patients who experienced a complete
response received hyperfractionated RT, whereas
those without complete response were offered
a total laryngectomy. Thirty-three (46.5%) of
patients achieved complete response to induction
chemotherapy and were irradiated. Four of these
patients experienced a tumor relapse, and all
underwent salvage surgery. Seventy-six percent
of the surviving patients had a functional larynx.
Despite not achieving complete response, 15
patients refused total laryngectomy and received
hyperfractionated RT. Seven patients demon-
strated tumor relapse and salvage surgery was
performed in 3 of them. Fifty percent of surviving
patients had a functional larynx. Twenty-two
patients without complete response underwent
total laryngectomy. No differences in overall sur-
vival were observed between groups. However, 10
patients in whom the larynx had been anatomi-
cally preserved developed functionless larynges
because of chronic toxicity from the treatment.
Majem et al13 concluded that patients with com-
plete response to induction chemotherapy for
laryngeal cancer have a high probability of cure
after hyperfractionated RT. Nevertheless, hyper-
fractionated RT is accompanied by a high degree
of toxicity that reduces preservation of laryngeal
function and may jeopardize QOL and overall sur-
vival.
Although induction chemotherapy offers the
ability to predict response and outcome of non-
surgical treatment, the results of the RTOG 91-
11 study showed that induction chemotherapy
followed by conventionally fractionated RT is not
the most effective nonsurgical approach for
laryngeal preservation.6 In this 3-arm phase III
study, patients with locally advanced cancer of
the larynx were randomly assigned to receive
either RT alone, or induction chemotherapy with
cisplatin followed by RT, or concomitant chemo-
radiation with cisplatin. After 2 years, the rate of
larynx preservation was highest among those
who received concomitant chemoradiation (88%)
and was significantly higher than after RT alone
(70%) or induction chemotherapy followed by RT
(75%). However, although locoregional control
was also highest after concomitant chemoradia-
tion, this difference did not translate into an
overall survival benefit. Five-year survival rates
were similar among all 3 treatment groups and
were highest in the group receiving induction
chemotherapy. Generally, survival rates were
lower in patients who required surgical salvage
in comparison to those who achieved successful
larynx preservation.14 Although this study has
been criticized, as previously mentioned, con-
comitant chemoradiation is currently the most
popular and widely applied nonsurgical app-
roach for larynx preservation.9,15
CHEMOTHERAPY ALONE
In 2007, Bonfils et al16 evaluated, in a retrospec-
tive study, the results of chemotherapy alone in
patients with invasive squamous cell carcinoma of
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the larynx had achieved a complete clinical
response after an induction chemotherapy proto-
col. The survival rate of the complete responder
group was significantly higher than that of the
incomplete responder group subsequently treated
with conventional modalities. No statistically sig-
nificant difference was noted between the 2
groups in terms of local and nodal recurrence. The
authors suggested that chemotherapy alone is a
viable option in selected patients with carcinoma
of the larynx who achieved a complete clinical
response after an induction chemotherapy proto-
col. This therapeutic approach allows surgery
and/or RT to be reserved for the management of
metachronous second primary tumors.
Recently, Worden et al17 used the response to
an initial course of induction chemotherapy in
patients with stages III or IV cancers, to select
complete histologic responders for exclusive
chemotherapy treatment. Preliminary analysis
indicated excellent primary site control and organ
preservation but inadequate regional tumor con-
trol with chemotherapy alone.
Although the results of these studies are of in-
terest, current treatment guidelines indicate that
chemotherapy alone should be used only in clini-
cal trials, in patients with a complete clinical
response following 3 courses of neoadjuvant
chemotherapy.
MOLECULAR THERAPY
For patients who experience treatment failure
with first-line therapy for recurrent or meta-
static disease, a median overall survival of 3 to 4
months has been observed after treatment with
second-line chemotherapy.18 There is, therefore,
a need for new therapeutic strategies focused on
molecular targets. The 2 targeting strategies
that have proven most successful in clinical
applications thus far have been small-molecule
tyrosine kinase inhibitors (gefitinib and erloti-
nib) or monoclonal antibodies directed against
the epidermal growth factor receptor (EGFR),
such as cetuximab. The EGFR and its ligands
have been recognized as critical proteins in the
development and survival of epithelial tissues,
and the great majority of squamous cell car-
cinomas of the head and neck (SCCHN) ex-
press EGFR. Inhibition of EGFR signaling by
small molecules, monoclonal antibodies directed
against ligands or receptors, immunotoxin conju-
gates, or antisense oligonucleotides has demon-
strated important activity in different models of
SCCHN.19 Recently, a multinational, random-
ized study comparing the effect of RT alone with
RT plus cetuximab showed that the median dura-
tion of loco-regional control was 24.4 months
among patients treated with cetuximab plus RT
and 14.9months among those given RTalone. Sim-
ilar results were observed concerning the median
duration of overall survival, which were 49.0
months among patients treated with combined
therapy and 29.3months among those treated with
RT alone.20 These results were most prominent in
patients with oropharyngeal primary tumors, with
little difference in outcome for patients with laryn-
geal or hypopharyngeal cancers.
On the other hand, reports of the combination
of gefitinib or erlotinib with cytotoxic chemother-
apy have been presented showing a 50% and 78%
overall response rate, respectively.21 It is also
apparent that these agents and many others
have, on average, more limited toxicity than do
traditional chemotherapeutic agents. Their effi-
cacy must be assessed using additional parame-
ters, including disease stabilization and QOL
instruments, as well as phase III trials.
FUNCTION, QUALITY OF LIFE, AND COST OF
TREATMENT
Improved cure rates, prolonged disease-free sur-
vival, and organ preservation are 3 of the primary
goals of the treatment of advanced laryngeal can-
cer. While improved cure rates and prolonged
disease-free survival are the primary focus of all
cancer therapy, the implicit purpose of organ pres-
ervation is improved function and QOL. However,
preservation of an organ does not equate to con-
servation of organ function.22,23 Therefore, the lit-
erature related to this topic must be interpreted
carefully. Preservation of the larynx says nothing
about the presence of a tracheotomy, the quality of
voice, or the presence of dysphagia and depend-
ence on gastrostomy feedings.
There are few studies evaluating the QOL spe-
cifically related to swallowing. In 2006, Dworkin
et al24 evaluated a series of subjects treated for
advanced laryngeal cancer with nonsurgical ther-
apy for swallowing function, time from treatment
to swallowing, and sequelae of nonsurgical ther-
apy. The study included 14 patients, all of whom
were treated with 7000 cGy using standard exter-
nal beam RT to the primary site, and 5000 cGy to
the ipsilateral neck (1 patient excluded). Two
patients received RT alone, whereas several
patients received 3 courses of neoadjuvant cisplatin
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and 5-fluorouracil, followed by 3 courses of concur-
rent cisplatin and RT. Patients were evaluated
retrospectively using fiberoptic endoscopic evalu-
ation of swallowing and patient interviews to eval-
uate the patients’ perceived swallowing function
and diet. In this study, 10 of 14 patients had mild
to severe dysphagia, and there was no significant
difference between those evaluated early in the
course of therapy (less than 1 year) or later (more
than 1 year after therapy). Five patients required
a tracheotomy during the course of therapy, and
only 2 patients were decannulated following ther-
apy. Four patients required gastrostomy tubes,
and only 2 patients had the tubes removed follow-
ing therapy. One patient suffered an RT-induced
oropharyngeal stricture. In this study, all the
patients suffered from ‘‘substantial swallowing
difficulties’’ following organ preservation therapy.
Not unlike other studies,25–27 more than 90% of
patients suffered abnormal swallowing function,
including pooling of secretions and trace aspira-
tion following treatment.
These findings are in stark contrast to those
reported by Fung et al,28 who also evaluated the
impact of organ preservation therapy on voice and
swallowing therapy in patients with advanced
cancers. They found that voice-related QOL was
better in patients after chemoradiation when com-
pared with total laryngectomy. They also found
that while swallowing function was good in all
patients, those with an intact larynx were more
likely to obtain nutrition by oral intake without
supplements. An explanation of the differing con-
clusions of these studies might be inferred from
the criteria employed to define satisfactory swal-
lowing function. In the study by Fung et al,28 the
definition of satisfactory function was nutritional
mode consisting of oral intake alone without
nutritional supplements. Such factors as pooling
of saliva or minimal aspiration, employed in many
of the other studies, were not considered.
In 2007, Nguyen et al29 compared incidence
and degree of aspiration by barium swallow exam-
ination in 43 patients, free of tumor after treat-
ment, who complained of aspiration after chemo-
radiation (22 patients) or RT alone (21 patients).
Aspiration occurred in 12 patients (54%) of the
chemoradiation group, and 7 patients (33%) of the
RT alone group. The difference was not statisti-
cally significant (p 5 .13). There was a high pro-
portion of patients with large tumors in the che-
moradiation group, although not statistically sig-
nificant. The authors suggest that this trend
toward aspiration may be related to tumor size, as
well as the additional toxic effects of chemotherapy,
and that the lack of significance was due to small
sample size. The article does not make clear the
overall incidence of dysphagia and aspiration
among all patients treated, as the study was con-
fined only to patientswho complained of dysphagia.
Loss of laryngeal function is often attributed to
chondronecrosis. In 2006, Zbären et al30 per-
formed a retrospective study on 341 patients
treated by RT alone or radiochemotherapy. The
incidence of chondroradionecrosis in 341 irradi-
ated patients was 5%. Tumor was present in 6 of
10 patients who underwent surgery for chondro-
necrosis. Chondronecrosis was often undetectable
on radiographic examination. The authors con-
cluded that chondronecrosis was rare. When pres-
ent, tumor recurrence often was situated beneath
an intact mucosa and was not evident on endo-
scopic examination.
Because the overall survival rates associated
with surgical and nonsurgical therapies are not
appreciably different, the focus of recent litera-
ture has been on the impact of therapy on QOL,
the cost of therapy, and the ability to achieve
reproducible results with nonsurgical treatment
regimens. Assessing QOL is a difficult task.
Hanna et al31 reviewed 42 patients with advanced
stages III or IV cancer of the larynx that were
treated with either concurrent chemoradiother-
apy or laryngectomy with postoperative RT. QOL
was measured using the European Organization
for Research and Treatment of Cancer Quality of
Life Questionnaire-C30 (EORTC QLQ-C30) in
tandem with the head and neck module (EORTC
QLQ-H&N35). Hanna et al31 found no statisti-
cally significant differences in the overall QOL
between the 2 groups. This study is unique in that
a functional subscale analysis was performed and
the authors found that surgery patients reported
significantly greater difficulties with smell and
taste, use of painkillers, and coughing, whereas
chemoradiation patients reported significantly
greater problems with xerostomia. The authors
concluded that both chemoradiation and laryngec-
tomy impact negatively on QOL in different ways.
Although differences in QOL could be detected by
functional and subscale analyses, the overall QOL
scores of both groups were similar.
The conflicting data on QOL has prompted
some to consider the cost of therapy as a consider-
ation for choice of therapy. Davis et al32 set
out to perform a cost minimization analysis of
total laryngectomy with postoperative RT versus
induction chemotherapy with subsequent RT in
Treatment of Patients with Advanced Laryngeal Cancer HEAD & NECK—DOI 10.1002/hed January 2008 107
patients with advanced (stages III or IV) squa-
mous cell carcinoma of the larynx. The authors
employed a decision-analysis model using data
from peer-reviewed trials, case series, meta-anal-
yses, and Medicare diagnosis-related group reim-
bursement rates. The authors found that total
laryngectomy with postoperative RT cost nearly
$3000 U.S. dollars less than organ preservation
treatment for advanced laryngeal cancer. The
authors suggested that cost and patient prefer-
ence should be considered when establishing a
treatment modality for patients with advanced
laryngeal cancer.
AGE
In addition to the factors of function, QOL, and
cost, consideration must be given to the age and
comorbid status of the patient. According to the
Department of Health andHuman Services report
on aging,33 persons 65 years or older numbered
36.3 million in 2002 and represented 12.4% of the
United States population; or about 1 in every 8.
By 2030, there will be about 71.5 million older per-
sons, constituting 20% of the population. The
elderly represent the fastest growing subpopula-
tion in North America and Europe. As the aging
population grows, the number of aged with
advanced laryngeal cancer will also grow. Many of
the physiologic changes associated with age do not
represent a direct risk for surgical complications
or complications related to chemoradiation.
Nevertheless, the physiologic changes that are
characteristic of advanced age can result indi-
rectly in a higher risk of morbidity. The normal
age-related decline in immunologic function, re-
nal function, and vascular compliancemay predis-
pose elderly patients to complications of therapy
and therefore must be carefully evaluated.
Emerging data from meta-analyses of concurrent
chemoradiation protocols indicate a decreasing
benefit with increasing patient age and lack of sig-
nificant benefit when chemotherapy is added to
RT in patients over the age of 70 years.34
The shift toward nonsurgical therapy for the
management of advanced laryngeal cancer has
generated considerable debate as to whether el-
derly patients can tolerate chemoradiation ther-
apy for a period of 2 to 3 months. The majority of
chemotherapy protocols do not include elderly
patients in their studies. Often not addressed is
the anecdotal observation that salvage surgery in
elderly individuals may be extremely complex and
such patients may not tolerate salvage surgery.
Clayman et al35 reviewed 43 patients aged 80
years and older in a case-controlled study. Only
23.3% of the octogenarians were treated with
adjuvant therapy, whereas 44.1% of the younger
controls received adjuvant therapy. Clayman
et al35 found that multimodality therapy among
the octogenarian population may be limited by a
patient’s ability to tolerate therapy. Similarly,
postoperative RT may not be tolerated well by
elderly patients. The authors point out that fol-
lowingmajor surgery, the patient may refuse post-
operative RT, especially if postoperative complica-
tions had occurred. Clayman et al35 state that the
psychosocial status of elderly patients has a sig-
nificant impact on the course of the disease, high-
lighting both the predilection for less aggressive
and substandard therapy in the elderly and the
likelymisperception that agemay adversely affect
disease-free survival.
There is a paucity of data to suggest that age
alone is associated with a higher risk of surgical
complications and in fact, the great majority of
studies assessing the impact of age on surgical
morbidity suggest no relationship between ad-
vanced age and surgical morbidity.36–39 However,
as mentioned earlier, the comorbidities associated
with age may indirectly affect an elderly patient’s
ability to tolerate surgery and prolonged anesthe-
sia. One recent study reviewed the American
College of Surgeons National Surgical Quality Im-
provement Program database for patient demo-
graphics, preoperative risk factors, intraoperative
risk factors, and 30-day outcomes with a focus on
those aged 80 years and older.40 The authors
reviewed 7696 surgical procedures and found that
hypertension and dyspnea were themost frequent
risk factors in those aged 80 years and older. Pre-
operative transfusion, emergency operation, and
weight loss best predicted morbidity for those 80
years of age and older. They also noted the Ameri-
can Society of Anesthesiologists’ classification,
which predicts mortality across all age groups. A
30-minute increment of operative duration
increased the odds of mortality by 17% in patients
older than 80 years, and postoperative morbidity
and mortality increased progressively with age.
Age was statistically significantly associated with
cardiovascular, renal, respiratory, and wound-
healing complications. This study is highlighted
because it is one of the few studies that suggest
that age may be related to surgical morbidity.
More importantly, this study defines factors that
can be controlled prior to surgery in an effort to
reduce the risk of surgery.
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CONCLUSIONS: SELECTION OF OPTIMAL
TREATMENT
There is excellent data to support the use of induc-
tion chemotherapy as a predictor of radiosensitiv-
ity and for selection of patients for definitive RTor
laryngectomy. Concomitant chemoradiation offers
the highest chance of laryngeal preservation, but
with a significant incidence of functional problems
affecting deglutition, need for tracheotomy, and
QOL. There is also data to suggest that other fac-
tors, including cost, age, and patient comorbidity,
should be considered in the decision-making pro-
cess. In the final analysis, every patient is unique,
and therefore, no single therapeutic modality is
ideal for every patient.
Organ preservation protocols and endo-
scopic resection have demonstrated clear pro-
gress concerning posttreatment function of
patients with laryngeal carcinomas. However,
according to the National Cancer Data Base,
survival has decreased among patients with
laryngeal cancer during the past 2 decades in
the United States.41 The most notable decline
in the 5-year relative survival occurred among
advanced-stage glottic cancer, early-stage
supraglottic cancers, and supraglottic cancers
classified as T3N0M0. An increase in the use
of chemoradiation has paralleled increased
mortality of patients with laryngeal cancer.
Although there has been an increase in endo-
scopic surgery for laryngeal cancer, lack of
data about surgical detail prevents conclusions
being drawn in relation to mortality.41 There-
fore, it is of paramount importance to critically
evaluate treatment protocols and continue to
seek more effective strategies to provide both
better QOL and improved survival rates.
Thus choice of treatment has to take into con-
sideration patient factors, such as performance
status, access to support services and to close fol-
low-up, and institutional factors such as swal-
lowing and nutritional support, and post-chemo-
radiation salvage surgery expertise. As we gain
an appreciation of the long-term morbidity asso-
ciated with nonsurgical therapy, the impact of
our therapeutic options should be carefully con-
sidered, particularly if survival rates are not
enhanced. It may be that primary surgical ther-
apy for some patients offers advantages that can-
not be realized by nonsurgical techniques. The
ability to perform conservation partial laryngec-
tomy procedures using open and transoral
approaches holds promise insofar as that a pro-
portion of patients with advanced cancers may
benefit from surgery with postoperative adju-
vant therapy at a dose that may be more favor-
ably tolerated.
The future of treatment of advanced laryngeal
cancer should include better patient selection and
identification of the most appropriate treatment
modalities for defined populations.42
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